Extension Study of P1101 in Japanese Patients Who Have Completed Phase 2 Single Arm Study in Polycythemia Vera (PV) Patients (Study A19-201) or Phase 3 Study in Essential Thrombocythemia (ET) Patients (Study P1101 ET)
Latest Information Update: 17 Jun 2022
At a glance
- Drugs Ropeginterferon alfa-2b (Primary) ; Aspirin
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Sponsors PharmaEssentia Corporation
- 13 Jun 2022 Planned number of patients changed from 27 to 67.
- 13 Jun 2022 Planned End Date changed from 31 Oct 2022 to 31 Oct 2024.
- 13 Jun 2022 Planned primary completion date changed from 30 Oct 2022 to 30 Oct 2024.